Currency In USD
| Previous Close | 13.87 |
| Open | 13.57 |
| Day High | 13.57 |
| Day Low | 12.01 |
| 52-Week High | 14.42 |
| 52-Week Low | 1.36 |
| Volume | 1.51M |
| Average Volume | 1.23M |
| Market Cap | 857.76M |
| PE | -16.13 |
| EPS | -0.78 |
| Moving Average 50 Days | 11.84 |
| Moving Average 200 Days | 6.49 |
| Change | -1.29 |
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China First pat
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire Inc.
Nov 06, 2025 12:01 PM GMT
PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug in Immune Thrombocytopenia (ITP
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
GlobeNewswire Inc.
Oct 21, 2025 11:00 AM GMT
WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with